| Identification | More | [Name]
Swertiamarine | [CAS]
17388-39-5 | [Synonyms]
SWERTIAMAIN
SWERTIAMARIN
(4ar-(4a-alpha,5-beta,6-alpha))-ranosyloxy)-4a-hydroxy
1h,3h-pyrano(3,4-c)pyran-1-one,4,4a,5,6-tetrahydro-5-ethenyl-6-(beta-d-glucopy
1H,3H-Pyrano[3,4-c]pyran-1-one,4,4.alpha.,5,6-tetrahydro-5-ethenyl-6-(.beta.-D-glucopyranosyloxy)-4.alpha.-hydroxy-,[4ar-(4.alpha.-.alpha.,5-.beta.,D-.alpha.)]-
3H-Pyrano[3,4-c]pyran-1-one,4,4.alpha.,5,6-tetrahydro-5-ethenyl-6-(.beta.-D-glucopyranosyloxy)-4.1H
4-c)pyran-1-one,4,4a,5,6-tetrahydro-5-ethenyl-6-(beta-d-glucopyranosyloxy)-4a-hydroxy-3h-pyrano(1
Swertiamarin(6CI,7CI,8CI)
Swertiamarine
Swertiamaroside
SWERTIAMARIN, 98+% BY HPLC
Swertiamarin std.
SWERTIAMARIN(P)
(5R,6S)-5-Ethenyl-4a-hydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4,5,6-tetrahydropyrano[5,4-c]pyran-1-one
glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-,(4aR,5R, 6S)-
Swertiamarin，Swertiamarine，Swertiamaroside
(4aR)-4aα-Hydroxy-5β-vinyl-6α-(β-D-glucopyranosyloxy)-4,4a,5,6-tetrahydro-1H,3H-pyrano[3,4-c]pyran-1-one
4aα-Hydroxy-6α-(β-D-glucopyranosyloxy)-5β-vinyl-4,4a,5,6-tetrahydro-1H,3H-pyrano[3,4-c]pyran-1-one
6α-(β-D-Glucopyranosyloxy)-4,4a,5,6-tetrahydro-4aα-hydroxy-5β-vinyl-1H,3H-pyrano[3,4-c]pyran-1-one | [Molecular Formula]
C16H22O10 | [MDL Number]
MFCD07783984 | [Molecular Weight]
374.34 | [MOL File]
17388-39-5.mol |
| Chemical Properties | Back Directory | [Melting point ]
113-114° | [alpha ]
D20 -127° (c = 1 in 96% ethanol) | [Boiling point ]
649.3±55.0 °C(Predicted) | [density ]
1.57±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
DMSO : 250 mg/mL (667.84 mM; Need ultrasonic) | [form ]
neat | [pka]
11.56±0.60(Predicted) | [color ]
White to Yellow to Orange | [λmax]
238nm(MeOH)(lit.) | [Merck ]
14,9010 | [BRN ]
55278 | [Stability:]
Hygroscopic | [InChIKey]
HEYZWPRKKUGDCR-QBXMEVCASA-N | [CAS DataBase Reference]
17388-39-5(CAS DataBase Reference) |
| Safety Data | Back Directory | [Safety Statements ]
24/25 | [WGK Germany ]
3 | [RTECS ]
UQ1366700 | [HS Code ]
29389090 | [Toxicity]
mouse,LD50,intraperitoneal,> 8gm/kg (8000mg/kg),BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY),Zhongcaoyao. Chinese Traditional and Herbal Medicine. Vol. 13, Pg. 464, 1982. |
| Hazard Information | Back Directory | [Uses]
Swertimarine is an extract from Enicostemma littorale which is an herb used in the treatment of type 1 and 2 diabetes. Used to sensitize the cells to hypolipidemic conditions and insulin. | [Definition]
ChEBI: Swertiamarin is a glycoside. | [Biological Activity]
Swertiamarin has shown potential as antiatherogenic agent by inhibiting HMG-CoA reductase activity in high cholesterol fed rats. The high cholesterol fed rats treated with Swertiamarin showed prevention of increased serum total cholesteroltriglyceridesLDLs and VLDLs. | [in vivo]
Swertiamarin (50, 75 mg/kg; once daily; 7 days; p.o.) has a lipid-lowering effect in hypercholesterolemic rats[1].
Swertiamarin (100, 200 mg/kg; once daily; 8 weeks; i.g.) has antioxidant and hepatoprotective effects on carbon tetrachloride induced rat hepatotoxicity through the Nrf2/HO-1 pathway[2].
Swertiamarin (2, 5, 10 mg/kg; once daily; 2 weeks; p.o.) prevents bone erosion in arthritis rats by regulating RANKL/RANK/OPG signaling transduction[3].
Swertiamarin (2, 5, 10 mg/kg; once daily; 2 weeks; p.o.) attenuates inflammatory mediators by regulating NF - κ B/I, κ B, and JAK2/STAT3 transcription factors in adjuvant induced arthritis rats[4]. | Animal Model: | Male Sprague Dawley (SD) rats with hypercholesterolemia induced by supplementing a diet rich in cholesterol[1]. | | Dosage: | 50, 75 mg/kg | | Administration: | Oral gavage (p.o.); once daily; 7 days | | Result: | Reduced serum total cholesterol, triglyceride concentration and atherosclerosis index. |
| Animal Model: | Male Sprague Dawley (SD) rat model of liver injury induced by CCl4[2]. | | Dosage: | 100, 200 mg/kg | | Administration: | i.g. ; once daily; 8 weeks | | Result: | Reduced the levels of serum marker enzymes ALT, AST, and ALP representing liver damage, and restored antioxidant enzyme activity and GSH content in rat liver.
|
| Animal Model: | Induced arthritis rat model by intradermal injection of 0.1ml Freund's complete adjuvant (FCA) in 1ml paraffin oil into the right hind paw of rats[3][4]. | | Dosage: | 2, 5, 10 mg/kg | | Administration: | Oral gavage (p.o.); once daily; 2 weeks | | Result: | Reduced calcium and TRAP, ACP, and ALP levels in serum and urine of arthritis rats, and increased phosphorus and collagen levels[3]. Inhibited paw thickness, lysosomal enzyme levels, and increased body weight in rats[4]. |
|
|
|